| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/27/2011 | US20110020458 Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
| 01/27/2011 | US20110020434 Nanoparticle arsenic-platinum compositions |
| 01/27/2011 | US20110020430 Novel mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy |
| 01/27/2011 | US20110020406 Viral inactivation process |
| 01/27/2011 | US20110020405 Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant |
| 01/27/2011 | US20110020404 Diagnostic method and kit |
| 01/27/2011 | US20110020403 immunizing composition |
| 01/27/2011 | US20110020402 Method For Identification, Isolation And Production Of Antigens To A Specific Pathogen |
| 01/27/2011 | US20110020401 Tissue targeted antigenic activation of the immune response to treat cancers |
| 01/27/2011 | US20110020400 Probiotic bifidobacterium strains |
| 01/27/2011 | US20110020399 Vaccines and Immunomodulatory Therapies for Tularemia |
| 01/27/2011 | US20110020398 Novel peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus |
| 01/27/2011 | US20110020397 Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as hbv and hdv entry inhibitors |
| 01/27/2011 | US20110020396 HIV Envelope-CD4 Complexes and Hybrids |
| 01/27/2011 | US20110020395 Probiotics for use in expecting female mammals for enhancing the immunity of their offsprings |
| 01/27/2011 | US20110020394 Pcv2 orf2 virus like particle with foreign amino acid insertion |
| 01/27/2011 | US20110020393 Method of Producing Japanese Encephalitis Vaccine Stably Storable Over Long Time and Use of the Vaccine |
| 01/27/2011 | US20110020392 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| 01/27/2011 | US20110020391 Recombinant modified vaccinia virus ankara (mva)-based vaccine for the avian flu |
| 01/27/2011 | US20110020390 Meningococcal fhbp polypeptides |
| 01/27/2011 | US20110020388 Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
| 01/27/2011 | US20110020387 Malaria vaccine |
| 01/27/2011 | US20110020386 Vaccines and compositions against streptococcus pneumoniae |
| 01/27/2011 | US20110020385 COMBINATIONS OF PNEUMOCOCCAL RrgB CLADES |
| 01/27/2011 | US20110020384 Therapeutic tb vaccine |
| 01/27/2011 | US20110020383 Novel genes and proteins of brachyspira hyodysenteriae and uses thereof |
| 01/27/2011 | US20110020382 Nucleic acid and amino acid sequences relating to staphylococcus epidermidis for diagnostics and therapeutics |
| 01/27/2011 | US20110020381 Influenza vaccine formulation |
| 01/27/2011 | US20110020380 Human Tumor Necrosis Factor TR18 and Methods Based Thereon |
| 01/27/2011 | US20110020379 Cobalamin Assay |
| 01/27/2011 | US20110020378 Self-assembling peptide nanoparticles useful as vaccines |
| 01/27/2011 | US20110020377 Aminopyrimidines useful as inhibitors of protein kinases |
| 01/27/2011 | US20110020376 Aminopyrimidines useful as inhibitors of protein kinases |
| 01/27/2011 | US20110020375 Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use |
| 01/27/2011 | US20110020374 Expression system for modulating an immune response |
| 01/27/2011 | US20110020373 Ige directed dna vaccination |
| 01/27/2011 | US20110020372 Follistatin domain containing proteins |
| 01/27/2011 | US20110020371 Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery |
| 01/27/2011 | US20110020370 Slc7a5 directed diagnostics and therapeutics for neoplastic disease |
| 01/27/2011 | US20110020369 Engineered anti-tslpr antibodies |
| 01/27/2011 | US20110020368 Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
| 01/27/2011 | US20110020367 Methods of Evaluating Transplant Rejection |
| 01/27/2011 | US20110020366 Use of benzophenone derivative or salt thereof and tnf alpha inhibitor in combination and pharmaceutical composition containing the derivative or salt thereof and the inhibitor |
| 01/27/2011 | US20110020365 Methods and Compositions for Identifying, Diagnosing, and Treating Neuroblastoma |
| 01/27/2011 | US20110020364 Methods and compositions involving pbef inhibitors for lung inflammation conditions and diseases |
| 01/27/2011 | US20110020363 Monoclonal antibody against interleukin-13 receptor alpha 1 (il-13ralpha1) |
| 01/27/2011 | US20110020362 Adrenergic stimulation mediates hypersensitivity by inducing nerve growth factor expression |
| 01/27/2011 | US20110020361 Human anti-mesothelin monoclonal antibodies |
| 01/27/2011 | US20110020360 Targeted binding agents directed to pdgrf-alpha and uses thereof |
| 01/27/2011 | US20110020359 Methods and compositions for treating neuronal damage or degeneration |
| 01/27/2011 | US20110020358 Methods and Compositions for Detecting Amyotrophic Lateral Sclerosis |
| 01/27/2011 | US20110020357 Anti human immunodeficiency antibodies and uses thereof |
| 01/27/2011 | US20110020356 Therapeutic clostridium difficile antibody compositions |
| 01/27/2011 | US20110020355 Treatment and prevention of gardnerella vaginalis infections |
| 01/27/2011 | US20110020354 G-protein coupled receptor ligands and methods |
| 01/27/2011 | US20110020353 Antibodies and related molecules that bind to 161p2f10b proteins |
| 01/27/2011 | US20110020352 Endogenous retroviruses up-regulated in prostate cancer |
| 01/27/2011 | US20110020351 Novel polypeptide esdn, polynucleotides encoding the polypeptide, and utility of the polypeptide |
| 01/27/2011 | US20110020350 Contraceptives Based on SP22 and SP22 Antibodies |
| 01/27/2011 | US20110020349 Anti-factor xi monoclonal antibodies and methods of use thereof |
| 01/27/2011 | US20110020348 Pharmaceutical compositions and methods using secreted frizzled related protein |
| 01/27/2011 | US20110020347 Anti-brak (cxcl14) human monoclonal antibody and use thereof |
| 01/27/2011 | US20110020346 Anti-vegf antibodies |
| 01/27/2011 | US20110020345 Drug fusions and conjugates |
| 01/27/2011 | US20110020344 Human monoclonal antibodies specific for cd22 |
| 01/27/2011 | US20110020343 Auristatin drug linker conjugates |
| 01/27/2011 | US20110020342 Igf-1 fusion polypeptides and therapeutic uses thereof |
| 01/27/2011 | US20110020341 Novel multidrug resistance-associated polypeptide |
| 01/27/2011 | US20110020340 Antibody-light fusion products for cancer therapeutics |
| 01/27/2011 | US20110020339 Methods of treatment |
| 01/27/2011 | US20110020338 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes |
| 01/27/2011 | US20110020337 Methods for treating conditions associated with masp-2 dependent complement activation |
| 01/27/2011 | US20110020336 Combination Of A Beta-Glucan And An EGF Receptor Antagonist For The Treatment Of Cancer And Infection |
| 01/27/2011 | US20110020335 Treatment of Cancers Expressing p95 ErbB2 |
| 01/27/2011 | US20110020334 Methods for treating and preventing brain tumors based on bone morphogenetic proteins |
| 01/27/2011 | US20110020333 Angiogenesis Pathway Gene Polymorphisms for Therapy Selection |
| 01/27/2011 | US20110020332 Prevention of tumors with monoclonal antibodies against neu |
| 01/27/2011 | US20110020331 N-glycosylated antibody |
| 01/27/2011 | US20110020330 Antibody inhibitors of gdf-8 and uses thereof |
| 01/27/2011 | US20110020329 Conjugates of anti-rg-1 antibodies |
| 01/27/2011 | US20110020328 Antibody formulations |
| 01/27/2011 | US20110020327 Purification of proteins |
| 01/27/2011 | US20110020326 Method of treating polycystic kidney disease |
| 01/27/2011 | US20110020325 Methods for reducing granulomatous inflammation |
| 01/27/2011 | US20110020324 Compound capable of binding s1p receptor and pharmaceutical use thereof |
| 01/27/2011 | US20110020323 Gram-positive bacteria specific binding compounds |
| 01/27/2011 | US20110020322 Crystallization of anti-cd20 antibodies |
| 01/27/2011 | US20110020321 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/27/2011 | US20110020320 Genetic Variants Contributing to Risk of Prostate Cancer |
| 01/27/2011 | US20110020319 Use of anti- sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
| 01/27/2011 | US20110020318 Inhibitors of the Interaction Between HMGB Polypeptides and Toll-Like Receptor 2 as Anti-Inflammatory Agents |
| 01/27/2011 | US20110020317 Breast tumour grading |
| 01/27/2011 | US20110020309 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergice disease |
| 01/27/2011 | US20110020295 Pre-transplant accommodated organs resistant to anti-donor immunity |
| 01/27/2011 | US20110020284 Probiotic bifidobacterium strains |
| 01/27/2011 | US20110020279 Rabies cure |
| 01/27/2011 | US20110020270 Treatment and prophylaxis |
| 01/27/2011 | US20110020269 Methods and compositions for modifying t cell immune responses and inflammation |
| 01/27/2011 | US20110020267 Tweak receptor |
| 01/27/2011 | US20110020237 Compositions and Methods for Inhibiting Drusen Formation and for Diagnosing or Treating Drusen-Related Disorders |